title: [Immediately effects of inhaled aerosolised iloprost in adult patients with severe pulmonary hypertension secondary to congenital heart diseases].
abstract: OBJECTIVE
  To investigate the immediately effects of inhaled aerosolized iloprost in adult patients with severe pulmonary arterial hypertension (PAH) secondary to congenital heart diseases (CHD).
  
  
  METHODS
  Adult patients with severe PAH secondary to CHD (n = 165) were included in this study. Right heart catheterization was performed, Pulmonary and systemic blood flow, the oxygen consumption VO(2) (ml/min) were calculated using Fick's principle. Pulmonary vascular resistances (PVR) were calculated with standard formulas and indexed to body surface area. Hemodynamic parameters were measured before and after iloprost inhalation (20 µg).
  
  
  RESULTS
  Post iloprost inhalation, heart rate, mean aortic pressure, pulmonary systolic pressure to aortic systolic pressure ratio all remained un changed (P > 0.05), while pulmonary artery pressure (PAP) were significantly reduced and Qp significantly increased from (7.2 ± 4.8) L/min to (9.9 ± 7.2) L/min (P < 0.01), PVR was also significantly reduced from (13.4 ± 8.7) Wood units to (9.5 ± 6.6) Wood units (P < 0.01), and left-to-right shunt volume increased from (3.2 ± 4.4) L/min to (5.5 ± 7.0) L/min (P < 0.01) and right-to-left shunt volume decreased from (1.0 ± 1.0) L/min to (0.7 ± 0.7) L/min (P < 0.01). Subgroup analysis showed that adult patients with patent ductus arteriosus and/or ventricular septal defects are more likely to develop severe pulmonary arterial hypertension or Eisenmenger syndrome than patients with atrial septal defects.
  
  
  CONCLUSIONS
  Inhaled Aerosolised iloprost use is effective and safe for adult patients with severe pulmonary arterial hypertension secondary to congenital heart diseases.
authors.affiliation: Guangdong General Hospital and Guangdong Cardiovascular Institute, Guangzhou 510100, China.
authors.forename: Cao-jin
authors.initials: CJ
authors.lastname: Zhang
authors.forename: Yi-gao
authors.initials: YG
authors.lastname: Huang
authors.forename: Jun-jun
authors.initials: JJ
authors.lastname: Shen
authors.forename: Tao
authors.initials: T
authors.lastname: Huang
authors.forename: Wen-hui
authors.initials: WH
authors.lastname: Huang
authors.forename: Ya-ling
authors.initials: YL
authors.lastname: Cui
authors.forename: Xin-sheng
authors.initials: XS
authors.lastname: Huang
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D005260:Female; D006330:Heart Defects, Congenital / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy*; D016285:Iloprost / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D014655:Vascular Resistance; D055815:Young Adult
chemical_list: D016285:Iloprost